Description:
In vitro diagnostic (IVD) products continue to experience robust sales growth across various categories, driven by new product innovations, global health spending shifts, regulatory changes, and evolving disease trends. In this dynamic market, companies are strategically acquiring new assets to enhance their revenue streams and foster product innovation. Kalorama Information’s latest report, Mergers and Acquisitions in the IVD Market, 2016-2019, details over 220 acquisitions in the diagnostics industry from 2016 to June 2019, offering a comprehensive look at the landscape of market transactions.
Report Highlights:
- Market Dynamics:
- The IVD market is constantly evolving with new products, regulatory changes, and shifts in global health spending.
- Strategic acquisitions are a key growth strategy for companies, providing both revenue and innovation boosts.
- Key Growth Segments:
- Next-Generation Sequencing (NGS): Driving precision medicine with advanced genomic technologies.
- Cancer Testing (Liquid Biopsy): Transforming cancer diagnostics with minimally invasive tests.
- Companion Diagnostics: Enhancing personalized treatment approaches with targeted diagnostics.
- Major Players and Activities:
- Detailed analysis of mergers and acquisitions involving leading companies, including Roche, Abbott, and Danaher.
- Insights into significant transactions and their market impacts.
- Detailed Acquisitions Listings:
- Selected Acquisitions of Diagnostic Companies, 2018 to June 2019
- Selected Acquisitions of Diagnostic Companies, 2016-2017
- Summaries of notable transactions from 2018 to 2019, such as:
- Danaher / Beckman Coulter Acquisitions in 2018 / 2019
- QIAGEN’s M&A Activity
- bioMérieux’s M&A Moves
- Illumina’s Acquisitions of PacBio and Edico Genome
- Summaries of notable transactions from 2016 to 2017, such as:
- Abbott’s Acquisitions, Divestures, and the Alere Deal
- Siemens’ Recent M&A Activity
- Konica Minolta’s Acquisitions of Ambry Genetics and Invicro
- Thermo Fisher’s Completion of the Patheon Acquisition
- Danaher’s Acquisition of Cepheid for Nearly $4 Billion
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
